新西兰将CAR T细胞癌症试验扩大到更多的医院,旨在治疗60名淋巴瘤患者。 New Zealand expands CAR T-cell cancer trial to more hospitals, aiming to treat 60 lymphoma patients.

马拉根研究所已将CAR T细胞治疗的第二阶段临床试验扩大到克赖斯特彻奇和奥克兰市医院,为更多的血癌病人带来了希望。 The Malaghan Institute has expanded its phase 2 clinical trial of CAR T-cell therapy to Christchurch and Auckland City hospitals, offering hope to more blood cancer patients. 这种疗法改变病人的免疫细胞 以对抗癌症 This therapy modifies patients' immune cells to fight cancer. 在惠灵顿开始的审判将在两年内治疗60名患复发淋巴瘤的成年人。 The trial, which began in Wellington, will treat 60 adults with relapsed lymphoma over two years. 扩大的目的是在新西兰广泛提供治疗,如果治疗成功的话,在新西兰提供标准护理。 The expansion aims to make the therapy widely available and a standard of care in New Zealand if successful.